Biosimilar medicines - Multistakeholder Event

• Invitation
• Agenda
• Privacy statement
• Summary report

Documents

• Impact of biosimilar competition in Europe (IQVIA, 2022)

Presentations

1. Introduction

• Introductory note
  John Ryan, Acting Deputy Director General for Health
  European Commission - Health & Food Safety
• How biosimilars impact my access to affordable medicines
  Patient speaker
• The impact of biosimilar competition in Europe: Presentation
  Per Troein, VP, Strategic partners, IQVIA
  Max Newton, Global supplier & association relations, IQVIA

2. Interchangeability of biosimilars

• Available evidence on interchangeability of biosimilars: Presentation
  Liese Barbier, Postdoctoral Researcher Pharmaceutical Sciences
  KU Leuven, Belgium
• Joint EMA-HMA statement on interchangeability: Presentation
  Steffen Thirstrup MD, Affiliate Professor and Chief Medical Officer
  European Medicines Agency (EMA)
• Q & A discussion

3. National biosimilar policies: switching and substitution

• Biosimilar policies in European Countries: Presentation
  Peter Schneider, Health Expert
  Austrian National Public Health Institute, GÖG (Austria)
• National perspectives from Cyprus: Presentation
  Olga Pitsillidou
  Officer Health Insurance Organization (Cyprus)
• National perspectives from Norway: Presentation
  Helga Festoy, Head of Unit
  Norwegian Medicines Agency (Norway)
• National perspectives from France: Presentation
  Nadia Amer, Project Officer
  Health Products Department National Health Insurance Fund CNAM (France)
• National perspectives from Denmark: Presentation
  Bente Glintborg, Senior rheumatologist and head of the DANBIO steering committee (Denmark)
• Q & A discussion

4. Building trust in oncology biosimilars: clinical practice

• Introduction: Presentation
  Peter Schneider, Health Expert
  Austrian National Public Health Institute, GÖG (Austria)
• Improving biosimilar access to the benefit of patients: Presentation
  Ward Rommel, Chair of ECL Access to Medicines Task Force
  Expert in Cancer Care at Kom op tegen kanker
• Perspective from an oncology clinician: Presentation
  Dr. Rosa Giuliani, Director
  Public Policy at the European Society for Medical Oncology (ESMO)
• The role of pharmacists in oncology biosimilar treatment: Presentation
  Dr. Tilman Schöning, Deputy Head
  Pharmacy Heidelberg University Hospital, Member of the European Society of Oncology Pharmacy (ESOP)
• The role of nurses in switch management between similar biological medicines: Presentation
  Dr. Adriano Friganovic, President
  European Specialist Nurses Organisation (ESNO) and World Federation of Critical Care Nurses (WFCCN)
• Q & A discussion

5. Untapping the full potential of biosimilars - Interactive panel discussion

• Simone Boselli, Public Affairs Director, EURORDIS-Rare Diseases Europe
• Yannis Natsis, Director of the European Social Insurance Platform (ESIP) 
• Julie Maréchal-Jamil, Director Biosimilar Policy & Science, Medicines for Europe 
• Dr. Rosa Giuliani, Director of Public Policy at the European Society for Medical Oncology (ESMO) 
• Despoina Makridaki, Director of Pharmaceutical Services at the Sismanoglio-Amalia Fleming General Hospital of Attica, Member of the Board and Scientific Committee of the European Association of Hospital Pharmacists (EAHP) 
• Ber Oomen, Executive Director of the European Specialist Nurses Organisation (ESNO) 

6. Closing words

• Closing words
  Harald Mische, Deputy Head of Unit for Medical Products
  European Commission - Health and Food Safety